ASK PHARM(002755)2022-12-04 10:12Group 1: Company Overview - The company is Beijing Aosai Kang Pharmaceutical Co., Ltd., with stock code 002755 and abbreviation Aosai Kang [1] - The meeting took place on September 12, 2019, in the company's conference room [2] Group 2: Key Products Under Development - The company is awaiting CDE approval for several key products, including: - Injection of Rabeprazole Sodium: First company to complete clinical research, currently under production application [3] - Injection of Lapatinib Sodium: Second company to complete clinical research, currently under production application [3] - The company is the only one using imported raw materials for Polymyxin E Sulfate, which has passed FDA and EU certifications [3] - The only domestic generic drug for Posaconazole Injection has completed clinical research and is expected to be the first to market in 2020 [3] Group 3: Innovation and R&D Progress - The company adheres to a "research as the source, health as the foundation" philosophy, focusing on innovative drugs and domestic first-generic drugs in four therapeutic areas: digestive ulcers, tumors, drug-resistant infections, and diabetes [4] - The company has established two major R&D platforms: chemical drug R&D and biopharmaceutical R&D, with collaborations with leading research institutions and universities [4][5] Group 4: Sales Expectations - The DPP-4 inhibitor, Saxagliptin Tablets (Aoxin Yi), has been approved in several provinces and is currently in the growth phase, with expectations for significant sales volume in the following year [5]